250 related articles for article (PubMed ID: 21861661)
1. Role of amyloid β1-42 and neuroimaging biomarkers in Alzheimer's disease.
Lista S; Emanuele E
Biomark Med; 2011 Aug; 5(4):411-3. PubMed ID: 21861661
[No Abstract] [Full Text] [Related]
2. New diagnostic criteria for Alzheimer's disease.
Zetterberg H
Biomark Med; 2011 Aug; 5(4):407-9. PubMed ID: 21861660
[No Abstract] [Full Text] [Related]
3. Alzheimer's disease biomarker development: a call to funding bodies.
Frisoni GB; Jack CR; Winblad B
Neurobiol Aging; 2017 Apr; 52():117-118. PubMed ID: 28317642
[No Abstract] [Full Text] [Related]
4. Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.
Schaffer C; Sarad N; DeCrumpe A; Goswami D; Herrmann S; Morales J; Patel P; Osborne J
J Lab Autom; 2015 Oct; 20(5):589-600. PubMed ID: 25424384
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for Alzheimer's disease.
Pauwels EK; Volterrani D; Mariani G
Drug News Perspect; 2009 Apr; 22(3):151-60. PubMed ID: 19440558
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for Alzheimer's disease. The research advances incrementally, but clinical use is still years away.
Harv Ment Health Lett; 2010 Nov; 27(5):1-3. PubMed ID: 21218612
[No Abstract] [Full Text] [Related]
7. The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.
Blennow K; Zetterberg H
Med Clin North Am; 2013 May; 97(3):369-76. PubMed ID: 23642576
[TBL] [Abstract][Full Text] [Related]
8. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap.
Frisoni GB; Perani D; Bastianello S; Bernardi G; Porteri C; Boccardi M; Cappa SF; Trabucchi M; Padovani A
Neurobiol Aging; 2017 Apr; 52():119-131. PubMed ID: 28317643
[TBL] [Abstract][Full Text] [Related]
10. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers.
Vos SJB; Gordon BA; Su Y; Visser PJ; Holtzman DM; Morris JC; Fagan AM; Benzinger TLS
Neurobiol Aging; 2016 Aug; 44():1-8. PubMed ID: 27318129
[TBL] [Abstract][Full Text] [Related]
11. [An overview of biomarkers in Alzheimer's disease].
Rong XF; Wang XL
Yao Xue Xue Bao; 2012 May; 47(5):551-7. PubMed ID: 22811995
[TBL] [Abstract][Full Text] [Related]
12. A cerebrospinal fluid biosignature for the diagnosis of Alzheimer's disease.
Barichello T; Giridharan VV; Dal-Pizzol F
Braz J Psychiatry; 2019; 41(6):467-468. PubMed ID: 31826090
[No Abstract] [Full Text] [Related]
13. Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease.
Parnetti L; Chiasserini D
Biomark Med; 2011 Aug; 5(4):479-84. PubMed ID: 21861669
[TBL] [Abstract][Full Text] [Related]
14. Understanding biomarkers of neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding.
Blennow K; Zetterberg H
Nat Med; 2015 Mar; 21(3):217-9. PubMed ID: 25742456
[No Abstract] [Full Text] [Related]
15. Differential diagnosis between Alzheimer's disease and other dementias: Role of cerebrospinal fluid biomarkers.
Farotti L; Sepe FN; Toja A; Rinaldi R; Parnetti L
Clin Biochem; 2019 Oct; 72():24-29. PubMed ID: 30998910
[No Abstract] [Full Text] [Related]
16. Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer disease in patients with mild cognitive impairment.
Dean RA; Shaw LM
Clin Chem; 2010 Jan; 56(1):7-9. PubMed ID: 19926774
[No Abstract] [Full Text] [Related]
17. Functional correlates of t-Tau, p-Tau and Aβ₁₋₄₂ amyloid cerebrospinal fluid levels in Alzheimer's disease: a ¹⁸F-FDG PET/CT study.
Chiaravalloti A; Martorana A; Koch G; Toniolo S; di Biagio D; di Pietro B; Schillaci O
Nucl Med Commun; 2015 May; 36(5):461-8. PubMed ID: 25646706
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic.
Morinaga A; Ono K; Ikeda T; Ikeda Y; Shima K; Noguchi-Shinohara M; Samuraki M; Yanase D; Yoshita M; Iwasa K; Mastunari I; Yamada M
Dement Geriatr Cogn Disord; 2010; 30(4):285-92. PubMed ID: 20861634
[TBL] [Abstract][Full Text] [Related]
19. [Biomarkers for Alzheimer's disease: after Alzheimer's disease neuroimaging initiative studies].
Shoji M
Brain Nerve; 2012 May; 64(5):497-504. PubMed ID: 22570063
[TBL] [Abstract][Full Text] [Related]
20. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
Oláh Z; Kálmán J; Tóth ME; Zvara Á; Sántha M; Ivitz E; Janka Z; Pákáski M
J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
